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ABSTRACT 
Objectives: To synthesize, characterize and evaluate antimicrobial properties of some novel fluorine based 2-aminothiazoles. 
Methods: The syntheses of some novel fluorine based 2-aminothiazoles have been described by using hypervalent iodine [I(III)] mediated 
approach. It was observed that this is the more general and promising method for the synthesis of any thiazole, but, when other methods work, the 
hypervalent iodine [I(III)] mediated approach generally gives better yields. The structures of these compounds have been characterized from the 
rigorous analysis of their IR, 1H NMR, MS and elemental analysis. These compounds were screened for their anti-microbial activity. 
Results: The results revealed that compounds 7d, 7f, 10a, 10b, 10c, 14e and 14f showed moderate to good antibacterial activity as compared with 
the standard drug Chloramphenicol. 
Conclusion: The two thiazole synthetic methods described herein use readily available reagents and both of them are easily feasible, the 
hypervalent iodine mediated approach for the synthesis of title compounds is more significant because, in spite of the better yields, it avoids the use 
of highly toxic and lachrymatory α-halogenoketone, thereby being more eco-friendlier. 
Keywords: Fluorine, 2-Aminothiazoles, Hypervalent iodine, α-Tosyloxyketones, Anti-microbial. 
 
INTRODUCTION 
The aminothiazoles have been reported by several researchers as an 
excellent precursor of a large variety of biologically active 
compounds such as antibiotics (cephalosporins [1-3], β-lactams [4], 
sulfathiazoles [5], etc.) and bactericides [6]. The application of 
aminothiazole derivatives in therapy and their utilization as agents 
are based upon cyclooxygenase inhibition [7-10] that led us to 
explore a convenient method for their synthesis.  
In addition to this, it has been observed that the incorporation of 
fluorine in many heterocyclic systems increased lipid solubility, thus 
enhancing the rates of absorption and transport of drug in vivo [11].  
By considering the wide range of applications of aminothiazoles and 
in continuation of our interest in hypervalent iodine [I(III)] 
mediated approach, we attempted the syntheses of some novel 
fluorine based 2-aminothiazoles (7a-g, 10a-c and 14a-f). 
 
MATERIALS AND METHODS 
All the chemicals required were purchased from the local suppliers 
and were purified by established methods. The melting points were 
recorded by open capillary method and are uncorrected. The purity 
and homogeneity of the synthesized compounds were routinely 
ascertained by the thin layer chromatography, performed on plates 
coated with silica gel-G. All compounds were isolated and purified 
by thin layer chromatography and column chromatography 
respectively. The visualization was done using iodine vapours and U. 
V. light chamber. The 1H NMR spectra were recorded on a Bruker 
300 MHz instrument using CDCl3 or DMSO-d6 solvents and TMS 
(Tetra methyl silane) as internal standard. Chemical shifts (δ) are 
reported in ppm and coupling constants J are given in Hz. IR spectra 
were recorded using KBr disks with a Buck Scientific IR M-500 
infrared spectrometer. The mass spectra was recorded on a JEOL 
JMS 600 mass spectrometer at an ionizing potential of 70eV (EI) 
electron impact ionization mode using the direct inlet system. 
Experimental 
Synthesis of 2-aryl/benzothiazolylamino-4-(2,4-difluorophenyl) 
thiazoles (7a-g, 10a-c) and 2-(2,4-difluorophenyl)amino-4-
arylthiazoles (14a-f) 
2,4-Difluoroacetophenone was prepared by the acetylation of 1,3-
difluorobenzene [12]. [Hydroxy(tosyloxy)iodo]benzene was prepared 
by the method of Neiland & Karele [13] and Koser et a.l [14]. 
Synthesis of phenyl thiourea (6a-g, 13)  
General Procedure: To aniline (0.1 mol) in water, concentrated HCl 
was added and the solution was warmed. A saturated solution of 
potassium thiocyanate (0.8 mol) in water was added slowly with 
stirring in above hydrochloride salt solution. Then the solution was 
heated for 4-5 hrs until the solution became turbid. The turbid 
solution was poured in cold water. The separated precipitate was 
filtered, washed with water and recrystallized from ethanol, so as to 
obtain pure compound phenylthiourea (Yield: 70-80%). 
Synthesis of 6-Substituted 2-aminobenzthiazole (8a-c) 
General procedure: The p-substituted aniline (0.1 mol) and 
ammonium thiocyanate (0.2 mol) in 150 ml of glacial acetic acid 
were cooled in an ice bath and stirred mechanically. To the solution, 
bromine (0.2 mol) in 25 ml of glacial acetic acid was added dropwise 
at such a rate to keep the temperature below 10 oC throughout the 
addition. Stirring was continued for additional thirty minutes after 
the bromine addition. The precipitate of the benzthiazole 
hydrobromide was collected, dissolved in hot water and basified 
with a saturated sodium carbonate solution. The free substituted 
benzthiazole was collected, washed with water and dried under 
vacuum. Recrystallization from ethanol gave 6-substituted 2-
aminobenzthiazoles 8a-c in good yield. 
Synthesis of 1-(6-Substituted benzothiazol-2-yl)thiourea (9a-c) 
procedure:General addedwasmol)(0.1chlorideBenzoyl
dropwise to ammonium thiocyanate (0.1 mol) in dry acetone 50 
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ml with stirring. After the initial reaction had subsided, the 
mixture was heated for 5 min and then a hot solution of 2-amino 
benzthiazole (0.1 mol) in dry acetone (50 ml) was added with 
constant stirring. After refluxing for1 hr, the mixture was poured 
into water. A crystalline solid precipitated out slowly. After 
filtration, the solid were heated with 10% NaOH solution (300 ml) 
and filtered again. The filtrate was acidified with conc. HCl and 
then made alkaline by an addition of a little ammonia. The solid so 
obtained was filtered, washed with water and dried. 
Recrystallization from ethanol gave 1-(6-Substituted benzothiazol-
2-yl)thiourea 9a-c in good yield. 
Synthesis of 2-aryl/benzothiazolylamino-4-(2,4-difluorophenyl) 
thiazoles (7a-g, 10a-c) and 2-(2,4-difluorophenyl)amino-4-
arylthiazoles (14a-f) 
Method A: Hypervalent iodine [I (III)] mediated approach 
Step I: Preparation of α-tosyloxy-2,4-difluoroacetophenone 
To a stirred solution of 2,4-difluoroacetophenone (0.01 mol) in 
acetonitrile was added HTIB (0.01 mol) and the reaction mixture 
was refluxed for 5 hrs. Excess of the solvent was distilled off and the 
residual mass was crystallized from ethanol. The product was 
further washed with cold ethanol and dried under vacuum, yield 
75%, m. p. 110-111°C.  
All other α-tosyloxyphenylketones were prepared using this 
standard procedure [15]. 
Step 2: Preparation of 2-aminothiazoles 7a-g, 10a-c and 14a-f 
General procedure: An equimolar mixture of α-
tosyloxyphenylketone (0.01 mol) and appropriate thiourea 
derivative (0.01 mol) in ethanol was refluxed for 3-4 hrs. The 
reaction mixture was then cooled. A crystalline solid was separated 
out. Filtered the solid, washed with saturated sodium bicarbonate 
solution and then with water. Recrystallized from ethanol gave title 
compounds. 
Method B: Hantzsch thiazole synthesis 
General procedure: An equimolar mixture of α-
bromomethylketone (0.01 mol) and appropriate thiourea derivative 
(0.01 mol) in ethanol was refluxed for 5-6 hrs. The reaction mixture 
was then cooled. A crystalline solid was separated out. Filtered the 
solid, washed with saturated sodium bicarbonate solution and then 
with water. Recrystallized from ethanol gave title compounds. 
7a: m. p. 210-211°C; IR (KBr): 3153 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.95-7.02 (2H, m, thiazole C5-H & C3'-H), 7.06-
7.13 (1H, dt, J=8.4 & 2.4 Hz, C5'-H), 7.34-7.53 (5H, m, C2''-H, C3''-H, C4''-
H, C5''-H & C6''-H), 8.06-8.13 (1H, td, J=8.4 & 6.2 Hz, C6'-H), 11.60 (1H, 
brs, N-H exchangeable with D2O); MS: M
+at m/z 288; Anal. Calcd. for 
C15H10F2N2S: C, 62.49 %; H, 3.50 %; N, 9.72 %. Found: C, 62.19 %; H, 
3.24 %; N, 9.98 %.  
7b: m. p. 145-146°C; IR (KBr): 3280 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.89-6.97 (1H, ddd, J=11.5, 8.6 & 2.7 Hz, C3'-H), 
6.99-7.05 (2H, m, thiazole C5-H & C5'-H), 7.39 (4H, s, C2''-H, C3''-H, C5''-
H & C6''-H), 8.03-8.11 (1H, td, J=8.6 & 6.3 Hz, C6'-H); MS: M
+at m/z 
322; Anal. Calcd. for C15H9ClF2N2S: C, 55.82 %; H, 2.81 %; N, 8.68 %. 
Found: C, 55.45 %; H, 2.94 %; N, 8.98 %.  
7c: m. p. 135-137°C; IR (KBr): 3292 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 2.38 (3H, s, C4''-CH3), 6.91-6.98 (2H, m, thiazole 
C5-H & C3'-H), 7.02-7.08 (1H, dt, J=8.6 & 2.4 Hz, C5'-H), 7.23-7.26 (2H, 
d, J=8.6 Hz, C2''-H & C6''-H), 7.27-7.30 (2H, d, J=8.6 Hz, C3''-H & C5''-H), 
8.06-8.14 (1H, td, J=8.6 & 6.5 Hz, C6'-H); MS: M
+at m/z 302; Anal. 
Calcd. for C16H12F2N2S: C, 63.56 %; H, 4.00 %; N, 9.27 %. Found: C, 
63.19 %; H, 4.24 %; N, 9.38 %.  
7d: m. p. 173-175°C; IR (KBr): 3204 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 3.85 (3H, s, C4''-OCH3), 6.88-6.95 (1H, ddd, 
J=12.5, 9.0 & 2.8 Hz, C3'-H), 6.98-7.01 (3H, m, C3''-H, C5''-H & thiazole 
C5-H), 7.04-7.11 (1H, dt, J=8.7 & 2.8 Hz, C5'-H), 7.37-7.40 (2H, d, J=9.2 
Hz, C2''-H & C6''-H), 7.96-8.03 (1H, td, J=8.7 & 5.7 Hz, C6'-H), 11.07 (1H, 
brs, N-H exchangeable with D2O); MS: M
+at m/z 318; Anal. Calcd. for 
C16H12F2N2OS: C, 60.37 %; H, 3.80 %; N, 8.80 %. Found: C, 60.03 %; 
H, 3.56 %; N, 9.07 %.  
7e: m. p. 242-244°C; IR (KBr): 3309 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.89-6.95 (1H, ddd, J=11.0, 8.9 & 2.3 Hz, C3'-H), 
6.97-7.02 (1H, dt, J=8.6 & 2.3 Hz, C5'-H), 7.23 (1H, s, thiazole C5-H), 
7.45 (1H, brs, N-H exchangeable with D2O), 7.63-7.66 (2H, d, J=9.0 
Hz, C2''-H & C6''-H), 8.09-8.17 (1H, td, J=8.6 & 6.8 Hz, C6'-H), 8.26-8.29 
(2H, d, J=9.0 Hz, C3''-H, C5''-H); MS: M
+at m/z 333. Anal. Calcd. for 
C15H9F2N3O2S: C, 54.05 %; H, 2.72 %; N, 12.61 %. Found: C, 54.09 %; 
H, 2.54 %; N, 12.31 %.  
7f: m. p. 150-151°C; IR (KBr): 3404 cm-1 (N-H stretch); 1H-NMR (300 
MHz, CDCl3): δ 6.86-6.93 (1H, ddd, J=11.5, 8.8 & 2.6 Hz, C3'-H), 6.94-
7.00 (1H, dt, J=8.8 & 2.6 Hz, C5'-H), 7.15 (1H, s, thiazole C5-H), 7.23-
7.33 (1H, dd, J=8.9 & 2.4 Hz, C5''-H), 7.41-7.42 (1H, d, J=2.4 Hz, C3''-H), 
7.47 (1H, brs, N-H exchangeable with D2O), 8.08-8.16 (1H, td, J=8.8 & 
6.7 Hz, C6'-H), 8.31-8.34 (1H, d, J=8.9 Hz, C6''-H); MS: M
+at m/z 357; 
Anal. Calcd. for C15H8Cl2F2N2S: C, 50.44 %; H, 2.26 %; N, 7.84 %. 
Found: C, 50.03 %; H, 2.24 %; N, 7.58 %.  
7g: m. p. 130-132°C; IR (KBr): 3198 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.85-6.93 (4H, m, C3'-H, C5'-H, C3''-H & C5''-H), 
7.09 (1H, s, thiazole C5-H), 8.07-8.23 (2H, m, C6'-H & C6''-H); MS: M
+at 
m/z 324; Anal. Found: C, 55.19 %; H, 2.24 %; N, 8.98 %. Calcd. for 
C15H8F4N2S: C, 55.55 %; H, 2.49 %; N, 8.64 %. 
10a: m. p. 258°C (decomp.); IR (KBr): 3222 cm-1 (N-H stretch); 1H-
NMR (300 MHz, DMSO-d6): δ 6.90-6.98 (1H, ddd, J=11.1, 8.8 & 2.2 Hz, 
C3'-H), 7.01-7.07 (1H, dt, J=8.8 & 2.2 Hz, C5'-H), 7.29 (1H, s, thiazole 
C5-H), 7.52-7.55 (1H, d, J=8.4 Hz, C5''-H), 7.73 (1H, s, C7''-H), 8.05-8.08 
(1H, d, J=8.4 Hz, C4''-H), 8.20-8.29 (1H, td, J=8.8 & 6.8 Hz, C6'-H), 11.67 
(1H, brs, N-H exchangeable with D2O); MS: M
+at m/z 379; Anal. 
Calcd. for C16H8ClF2N3S2: C, 50.59 %; H, 2.12 %; N, 11.06 %. Found: C, 
50.19 %; H, 2.24 %; N, 10.98 %.  
10b: m. p. 227-228°C; IR (KBr): 3157 cm-1 (N-H stretch); 1H NMR 
(300 MHz, DMSO-d6): δ 2.44 (3H, s, C6''-CH3), 6.90-6.97 (1H, ddd, 
J=11.3, 8.7 & 2.6 Hz, C3'-H), 7.01-7.07 (1H, dt, J=8.3 & 2.6 Hz, C5'-H), 
7.16-7.19 (1H, d, J=8.3 Hz, C5''-H), 7.27 (1H, s, thiazole C5-H), 7.43-
7.46 (1H, d, J=8.3 Hz, C4''-H), 7.52 (1H, s, C7''-H), 8.24-8.32 (1H, td, 
J=8.3 & 6.8 Hz, C6'-H), 12.02 (1H, brs, N-H exchangeable with D2O); 
MS: M+at m/z 359. Anal. Calcd. for C17H11F2N3S2: C, 56.81 %; H, 3.08 
%; N, 11.69 %. Found: C, 56.69 %; H, 3.25 %; N, 11.98 %.  
10c: m. p. 230-232°C; IR (KBr): 3156 cm-1 (N-H stretch); 1H NMR 
(300 MHz, DMSO-d6): δ 3.86 (3H, s, C6''-OCH3), 6.89-6.97 (2H, m, C3'-H 
& C5''-H), 7.01-7.07 (1H, dt, J=8.6 & 2.2 Hz, C5'-H), 7.26 (1H, s, thiazole 
C5-H), 7.49-7.52 (1H, d, J=8.8 Hz, C4''-H), 7.54 (1H, s, C7''-H), 8.23-8.31 
(1H, td, J=8.6 & 7.0 Hz, C6'-H), 12.01 (1H, brs, N-H exchangeable with 
D2O); MS: M
+at m/z 375. Anal. Calcd. for C17H11F2N3OS2: C, 54.39 %; 
H, 2.95 %; N, 11.19 %. Found: C, 54.69 %; H, 3.15 %; N, 11.08 %.  
14a: m. p. 190-192°C; IR (KBr): 3258 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.87-6.99 (2H, m, C3'-H & C5'-H), 7.19 (1H, s, 
thiazole C5-H), 8.03-8.06 (2H, d, J=8.8 Hz, C2''-H & C6''-H), 8.23-8.26 
(2H, d, J=8.8 Hz, C3''-H & C5''-H), 8.49-8.57 (1H, td, J=9.0 & 6.0 Hz, C6'-
H), 9.55 (1H, brs, N-H exchangeable with D2O); MS: M
+at m/z 333; 
Anal. Calcd. for C15H9F2N3O2S: C, 54.05 %; H, 2.72 %; N, 12.61 %. 
Found: C, 54.25 %; H, 2.40 %; N, 12.40 %.  
14b: m. p. 238-239°C; IR (KBr): 3204 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.84-6.90 (2H, m, C3'-H & C5'-H), 7.45-7.49 (2H, 
d, J=8.6 Hz, C2''-H & C6''-H), 7.51 (1H, s, thiazole C5-H), 7.74-7.77 (2H, 
d, J=8.6 Hz, C3''-H & C5''-H), 8.23-8.32 (1H, td, J=8.9 & 5.9 Hz, C6'-H), 
9.45 (1H, brs, N-H exchangeable with D2O); MS: M
+at m/z 365. Anal. 
Calcd. for C15H9BrF2N2S: C, 49.06 %; H, 2.47 %; N, 7.63 %. Found: C, 
49.09 %; H, 2.54 %; N, 7.31 %.  
14c: m. p. 172-173°C; IR (KBr): 3215 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.84-6.90 (2H, m, C3'-H & C5'-H), 7.31-7.34 (2H, 
d, J=8.4 Hz, C2''-H & C6''-H), 7.53 (1H, s, thiazole C5-H), 7.82-7.85 (2H, 
d, J=8.4 Hz, C3''-H & C5''-H), 8.25-8.33 (1H, td, J=8.9 & 6.0 Hz, C6'-H), 
9.49 (1H, brs, N-H exchangeable with D2O); MS: M
+at m/z 322. Anal. 
Calcd. for C15H9ClF2N2S: C, 55.82 %; H, 2.81 %; N, 8.68 %. Found: C, 
55.65 %; H, 2.65 %; N, 8.88 %.  
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14d: m. p. 188-189°C; IR (KBr): 3216 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 3.73 (3H, s, C4''-OCH3), 6.87-6.98 (2H, m, C3'-H & 
C5'-H), 7.21-7.24 (2H, d, J=9.0 Hz, C3''-H & C5''-H), 7.35 (1H, s, thiazole 
C5-H), 7.67-7.70 (2H, d, J=9.0 Hz, C2''-H & C6''-H), 7.96-8.03 (1H, td, 
J=8.6 & 6.0 Hz, C6'-H), 9.46 (1H, brs, N-H exchangeable with D2O); 
MS: M+at m/z 318; Anal. Calcd. for C16H12F2N2OS: C, 60.37 %; H, 3.80 
%; N, 8.80 %. Found: C, 60.17 %; H, 3.76 %; N, 8.50 %.  
14e: m. p. 165-167°C; IR (KBr): 3256 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.86-6.98 (2H, m, C3'-H & C5'-H), 7.21 (1H, s, 
thiazole C5-H), 7.58-7.64 (1H, t, J=8.9 Hz, C5''-H), 7.87-7.90 (1H, d, 
J=8.9 Hz, C6''-H), 8.15-8.18 (1H, d, J=8.9 Hz, C4''-H), 8.41 (1H, s, C2''-H), 
8.51-8.59 (1H, td, J=8.6 & 5.9 Hz, C6'-H), 9.56 (1H, brs, N-H 
exchangeable with D2O); MS: M
+ at m/z 333; Anal Calcd. for 
C15H9F2N3O2S: C, 54.05 %; H, 2.72 %; N, 12.61 %. Found: C, 54.35 %; 
H, 2.42 %; N, 12.51 %.  
14f: m. p. 186-187°C; IR (KBr): 3167 cm-1 (N-H stretch); 1H-NMR 
(300 MHz, CDCl3): δ 6.96-7.02 (2H, m, C3'-H & C5'-H), 7.19 (1H, s, 
thiazole C5-H), 7.41-7.59 (5H, m, C2''-H, C3''-H, C4''-H, C5''-H & C6''-H), 
8.01-8.08 (1H, td, J=8.4 & 6.2 Hz, C6'-H), 9.67 (1H, brs, N-H 
exchangeable with D2O); MS: M
+at m/z 288; Anal. Calcd. for 
C15H10F2N2S: C, 62.49 %; H, 3.50 %; N, 9.72 %. Found: C, 62.59 %; H, 
3.44 %; N, 9.58 %.  
Antibacterial activity 
The antibacterial activity of all the newly synthesized compounds 
was done by the Muller-Hinton agar-well diffusion assay technique. 
The stock solutions of all test compounds (100 mg/ml) were 
prepared by dissolving 100 mg of the test compound in DMSO (1 
ml). Chloramphenicol and DMSO were used as positive and negative 
controls, respectively. Twenty millilitres of molten and cooled MHA 
and 320 ml of each test bacterial culture were mixed (separate flasks 
were used for each bacterial culture) and poured in sterilized and 
labeled petri plates. The wells of 6 mm were punched in the 
solidified petri plates, aseptically. Fifty micro litters from stock 
solutions of all compounds as well as controls was added to each 
well of labeled petri plates and incubated at 35oC for 24 h. The 
diameter of the zone of growth inhibition around each well was 
measured after incubation using vernier caliper. The minimum 
inhibitory concentration (MIC) of compounds against Gram-positive 
and Gram-negative test bacteria was determined in the range 100 to 
40 mg/ml. All the test cultures were streaked on SCDA and 
incubated overnight at 37oC. Stock solution of each compound was 
prepared in DMSO and was appropriately diluted to get a final 
concentration of 100, 90, 80, 70, 60, 50 and 40 mg/ml. Standard 
antibiotic chloramphenicol was also diluted to get a final 
concentration in the same manner. 
DISCUSSION  
Several methods have been reported in the literature for the 
formation of thiazoles [16]. The most common method of thiazole 
synthesis involves the condensation of α-halogenoketones with 
thiourea (Hantzsch thiazole synthesis). However, the versatility of 
this reaction is somewhat limited by the difficulty in preparation, 
purification, toxicity and lachrymatory property of the intermediate 
α-halogenoketones [17]. 
Another similar and useful synthetic method [18] involves the use of 
hypervalent iodine reagents [I(III)] in organic synthesis. 
[hydroxy(tosyloxy)iodo]benzene (HTIB or Koser’s reagent) [19] is 
one of the hypervalent iodine reagents which has been recently used 
as an extremely important reagent providing new and useful 
synthesis of various heterocyclic compounds. One of the most 
important reactions of HTIB, particularly α-tosylation of carbonyl 
compounds, was first reported in 1982 by Koser et al. [20]. 
We first attempted to prepare the precursors α-tosyloxyketones 4 
and 12a-f required for this work which was easily obtained via 
synthetic route [15] starting from commercially available aryl 
ketones as formulated in schemes 1 and 3. 
The aryl thioureas 6a-g and 13 required for the formation of target 
compounds 7a-g and 14a-f were prepared by treating substituted 
aromatic amines with ammonium thiocyanate in acidic medium 
[21]. 
The various anilines on treating with 
bromine/ammoniumthiocyanate gave the corresponding 
benzothiazoles 8a-c [22] which on treatment again with 
ammoniumthiocyanate/benzoyl chloride yielded benzothiazolyl 
urease 9a-c [23].  
Thus, various α-tosyloxyketones were condensed with appropriate 
thiourea in refluxing ethanol yielded the targets compounds i. e. 2,4-
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The structural elucidation of final targets was mainly based on IR, 
1H NMR, MS and elemental analyses. The IR spectra of thiazoles 
7a-g, 10a-c and 14a-f showed an absorption band due to N-H 
stretching in the range of 3150-3410 cm-1. The 1H NMR spectrum 
of the recrystallized samples showed the presence of a sharp 
singlet due to C5-H of the thiazole ring which confirmed the 
formation of the thiazole ring. It was further characterized by MS 
and elemental analysis. 
 
For a comparative study of yield (%), the title compounds 7a-g, 10a-
c and 14a-f were also prepared by Hantzsch thiazole synthesis. 
Outline of which is shown in Scheme 4.  
The results obtained from the respective methods are depicted in 
Table 1. 
As shown in Table 1, the comparison of yields (%) relating to the 
compounds synthesized from the recently known hypervalent 
iodine mediated approach and those from earlier method reveals 
that I(III) mediated approach is superior to the conventional 
Hantzsch thiazole synthesis. 
Evaluation of antibacterial Activity 
The newly synthesized compounds 7a-g, 10a-c and 14a-d were 
tested for their antibacterial activity against S. aureus, E. coli, B. 
subtilis, P. aeruginosa, S. pyogens, K. terrigena and K. pneumonae. All 
the synthesized compounds were dissolved in DMSO and 
antibacterial activity studied by disc diffusion method. Compounds 
7d, 7f, 10a, 10b, 10c, 14e and 14f showed moderate to good 
antibacterial activity against several species as compared with 
standard drug chloramphenicol. 
 
Table 1: Comparison of yields (%) relating to the compounds synthesized by two methods 
Compound R’ Yield (%) 
  Method Aa Method Bb 
7a H 98 92 
7b 4-Cl 85 73 
7c 4-CH3 97 91 
7d 4-OCH3 95 83 
7e 4-NO2 76 52 
7f 2,4-Cl2 89 72 
7g 2,4-F2 83 72 
10a Cl 73 58 
10b CH3 90 76 
10c OCH3 93 83 
14a 4-NO2 81 70 
14b 4-Br 79 51 
14c 4-Cl 82 56 
14d 4-OCH3 98 86 
14e 3-NO2 91 75 
14f H 87 73 
a) Hypervalent iodine [I (III)] mediated approach 
b) Hantzsch thiazole synthesis 
 
Table 2: Antibacterial activity of the compounds (7a-g, 10a-c and 14a-f) as MIC (μg/ml) 
Compound S. aureus E. coli B. subtilis P. aeruginosa S. pyogens K. terrigena K. pneumonae 
7a 100 90 90 80 -- -- 90 
7b 90 80 90 90 -- -- 100 
7c 80 90 80 90 90 100 90 
7d 90 70 80 70 80 90 80 
7e 100 80 90 80 90 70 90 
7f 70 90 100 80 70 80 100 
7g 90 70 -- 90 -- 70 -- 
10a 60 60 70 60 70 80 70 
10b 70 70 80 80 70 80 80 
10c 70 80 80 70 80 70 70 
14a -- 80 90 80 90 100 100 
14b 90 70 100 90 100 90 100 
14c 80 90 80 -- 100 90 -- 
14d 100 90 100 90 80 80 90 
14e 90 80 80 90 70 80 80 
14f 80 70 70 80 80 90 70 
Chloramphenicol 50 50 40 40 50 40 50 
Singh et al. 





The two thiazole synthetic methods described herein use readily 
available reagents and both of them are easily feasible, the 
hypervalent iodine mediated approach for the synthesis of title 
compounds is more significant because, in spite of the better yields, 
it avoids the use of highly toxic and lachrymatory α-halogenoketone, 
thereby being more eco-friendlier. All the synthesized compounds 
were dissolved in DMSO and antibacterial activity studied by disc 
diffusion method. Compounds 7d, 7f, 10a, 10b, 10c, 14e and 14f 
showed moderate to good antibacterial activity against several 
species as compared with the standard drug chloramphenicol. 
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